Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | PTPRC | P08575 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.45 |
| ▸ | MMP3 | P08254 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.36 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29448325 | 0.91 | KDM4E (0.62) | KDM4ETDP1PTPRCPTPN1ENPP2 | |
| SCHEMBL348813 | 0.91 | KDM4E (0.62) | KDM4ETDP1PTPRCPTPN1ENPP2 | |
| SCHEMBL23120221 | 0.87 | KDM4E (0.48) | KDM4ETDP1PTPRCPTPN1ENPP2 | |
| SCHEMBL1640831 | 0.87 | KDM4E (0.48) | KDM4ETDP1PTPRCPTPN1ENPP2 | |
| SCHEMBL3518141 | 0.87 | KDM4E (0.48) | KDM4ETDP1PTPRCPTPN1ENPP2 | |
| SCHEMBL14077416 | 0.84 | KDM4E (0.55) | KDM4ETDP1PTPRCPTPN1ENPP2 | |
| SCHEMBL1448749 | 0.84 | PTGS1 (0.53) | KDM4ETDP1CYP1A2CYP2A6NPC1 | |
| Isobutane SCHEMBL11549320 | 0.84 | KDM4E (0.55) | KDM4ETDP1PTPRCPTPN1ENPP2 | |
| SCHEMBL31292193 | 0.83 | KDM4E (0.48) | KDM4ETDP1PTPRCPTPN1ENPP2 | |
| SCHEMBL11272789 | 0.82 | CYP1A2 (0.51) | KDM4ETDP1PTPRCPTPN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10799496-B2 | Naphthylenyl compounds for long-acting injectable compositions and related methods | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-10-13 | — | — | US | disclosed |
| US-10799496-B2 | Naphthylenyl compounds for long-acting injectable compositions and related methods | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-10-13 | — | — | US | disclosed |
| WO-2020012248-A1 | NOVEL NAPHTHYLENYL COMPOUNDS FOR LONG-ACTING INJECTABLE COMPOSITIONS AND RELATED METHODS | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-01-16 | — | — | WO | disclosed |
| WO-2020012248-A1 | NOVEL NAPHTHYLENYL COMPOUNDS FOR LONG-ACTING INJECTABLE COMPOSITIONS AND RELATED METHODS | ALKERMES PHARMA IRELAND LIMITED (IE) | 2020-01-16 | — | — | WO | disclosed |
| EP-1296945-B1 | SULFONAMIDE DERIVATIVES | LILLY CO ELI (US) | 2004-08-04 | — | — | EP | disclosed |
| US-6703425-B2 | ADMINISTERING GLUTAMATE RECEPTOR POTENTIATOR TO TREAT PSYCHOLOGICAL AND NERVOUS SYSTEM DISORDERS | ELI LILLY AND COMPANY | 2004-03-09 | — | — | US | disclosed |
| US-20030229102-A1 | Sulfonamide derivatives | ELI LILLY AND COMPANY | 2003-12-11 | — | — | US | disclosed |
| EP-1296945-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2003-04-02 | — | — | EP | disclosed |
| WO-2001096289-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10799496-B2 | Naphthylenyl compounds for long-acting injectable compositions and related methods | OPRL1, OPRK1, OPRM1 | KDM4E 1937/4885TDP1 4269/4885PTPRC 3086/4885 |
| US-20030229102-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, SLC1A2 | KDM4E 2686/4885TDP1 2480/4885PTPRC 3291/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.